Hikma Pharmaceuticals PLC : There is still some upside potential
| Entry price | Target | Stop-loss | Potential |
|---|
|
GBX 1,911.5 |
GBX 2,100 |
GBX 1,800 |
+9.86% |
|---|
The timing appears opportune to go long in shares of Hikma Pharmaceuticals plc as we anticipate another pick-up in the underlying trend.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● The company has solid fundamentals for a short-term investment strategy.
● The company returns high margins, thereby supporting business profitability.
● The company is in a robust financial situation considering its net cash and margin position.
● Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● The company is not the most generous with respect to shareholders' compensation.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
HIKMA PHARMACEUTICALS PLC 
